Press Releases

Month Year

Month Year

Nov 30, 2021

Sanofi offers all employees worldwide 14 weeks paid parental leave to ensure workplace equality

* Regardless of gender or sexual orientation, employees welcoming a child into their family receive equal amount of paid time off
Nov 4, 2021

New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021
Oct 25, 2021

Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
Oct 22, 2021

Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

Pivotal trial met primary and all key secondary endpoints
Oct 20, 2021

FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option

Show per page

Print
Email page
RSS